Should Xpert® MTB/RIF be rolled out in low-income countries?

Int J Tuberc Lung Dis. 2012 May;16(5):702-3; author reply 703-4. doi: 10.5588/ijtld.12.0034.
No abstract available

Publication types

  • Letter
  • Kommentar

MeSH terms

  • Antitubercular Agents / pharmacology*
  • Humans
  • Nucleic Acid Amplification Techniques / methods*
  • Rifampin / pharmacology*
  • Tuberculosis / diagnosis*

Substances

  • Antitubercular Agents
  • Rifampin